This article summarizes noteworthy Canadian patent law decisions and developments from 2015.

1. Remedies in patent litigation

a. Non-infringing alternative defence introduced into Canadian patent law

A successful patentee in a patent infringement action is entitled to monetary compensation in relation to the acts of infringement.  In this regard, the patentee may elect to recover either its damages or the profits made by the infringer as a result of the infringement. 

With respect to damages, the Court will determine the financial harm suffered by the patentee as a result of the infringement.  In other words, the Court will consider what position the patentee would have been in but for the infringer’s infringement.  Traditionally, compensatory damages for a patentee mainly comprise the patentee’s lost profits on infringing sales it can prove (on a balance of probabilities) it would have made had the infringing product not been on the market, and a reasonable royalty for all other infringing sales. Until recently, the issue of damages was determined without factoring in what the infringer could or would have done differently. That is, the Court’s damages analysis focused solely on the harm suffered by the patentee due to the infringer’s acts of infringement. This is in contrast to an accounting of profits analysis, which may take into account any non-infringing alternatives available to an infringer.1

The law of damages changed in 2015 when the Federal Court of Appeal issued its decision inApotex Inc. v. Merck & Co., Inc.2015 FCA 171 (the “FCA Decision”). Prior to the FCA Decision, hypothetical non-infringing alternative (NIA) scenarios of a defendant were not considered when calculating patent infringement damages. However, the FCA Decision provided that, in certain situations, an infringer may now argue that it had an NIA available to it such that, for example, the infringer would have in any event made the sales, thereby defeating a patentee’s claim for lost profits.

In order for an infringer to successfully rely upon the NIA defence, various minimum criteria must be met, including that, at the time of infringement, the infringer had an adequate supply of product such that it could have sold the non-infringing alternative, and the infringer would have actually sold the non-infringing alternative product.

Although the FCA Decision changes the law of Canada by introducing the NIA defence, Apotex was ultimately not successful in its appeal of the lower Court decision, which granted Merck damages totaling a staggering $119 million plus interest (as discussed in greater detail here). Instead, the Court of Appeal held that Apotex neither could nor would have sold a non-infringing alternative product. 

Leave to appeal to the Supreme Court of Canada has been sought by Apotex.  An in-depth review of the FCA Decision and its implications is available here.

b. Cases addressing damages under section 8 of the PM(NOC) Regulations

2015 saw further setbacks for generics under section 8 of the PM(NOC) Regulations in their attempts to recover innovator profits rather than their own loss suffered. One case addressing this issue was Apotex v. Eli Lilly2015 ONCA 305, where the Ontario Court of Appeal (OCA) held that a generic cannot make a claim for innovator profits under the doctrine of unjust enrichment. The case is discussed further here.

Apotex argued that it was kept off the market because of a proceeding under the PM(NOC) Regulations commenced by Lilly in which Lilly was ultimately unsuccessful. Section 8 of thePM(NOC) Regulations states that a generic can recover any “loss suffered” from an innovator in this situation. Apotex pursued a claim in the Ontario Courts under the doctrine of unjust enrichment. The three part test to make out a claim for unjust enrichment requires: (a) an enrichment of the defendant; (b) a corresponding deprivation of the plaintiff; and (c) the absence of any juristic reason for the enrichment.

The OCA held that Apotex could not recover Lilly’s profits as Apotex suffered no corresponding deprivation. As Apotex had every right to claim its loss, any difference between this “loss suffered” and Lilly’s actual profits was not a deprivation to Apotex.

Apotex made the further argument that this potential difference between Lilly’s profits and Apotex’s loss should nonetheless be recoverable as they were “profits of wrongdoing”. Rejecting this argument, the OCA held that Apotex was an inappropriate party to make this claim, as Lilly had no equitable duty to Apotex and was not exploiting Apotex to its advantage.

Apotex has sought leave to the Supreme Court of Canada.

Low v. Pfizer2015 BCCA 506, was a decision of the BC Court of Appeal (BCCA). The case involved a potential class action on the basis that Pfizer overcharged the public for its VIAGRA product through asserting its ultimately invalid patent covering the use of sildenafil for the treatment of ED in proceedings under the PM(NOC) Regulations.

The most interesting aspect of Low is the BCCA’s use of the “complete code” argument to dismiss the class action. In particular, it was held that the Patent Act and the related legislation (such as the PM(NOC) Regulations) constitute a complete code that “forecloses parallel civil actions”. An in-depth discussion of Low can be found here.

Finally, the Supreme Court of Canada dismissed the appeal of Sanofi in the Ramipril section 8 damages case.2 The SCC endorsed the reasons of the Federal Court of Appeal. The FCA’s reasons are discussed here.

2. Canada and the Trans-Pacific Partnership

The Trans-Pacific Partnership (TPP) is a trade agreement involving a dozen Pacific region countries that, collectively, make up 36% of global GDP (or close to $30 trillion in GDP). The TPP agreement addresses trade matters in relation to numerous industries, as well as certain intellectual property laws of TPP countries.

Specifically with respect to patents, the TPP agreement is notable in that it requires Canada to implement patent term extension in situations where there have been unreasonable delays (i.e., delays of more than five years from filing or three years from a request for examination). Making patent term extension available to patentees in Canada would bring Canada more in-line with countries such as the United States, which already has a regime for term extension. The TPP agreement also provides for patent term extension for pharmaceutical patent holders in situations where a patent was impacted by delays related to regulatory or marketing approvals, as well as other pharmaceutical-specific provisions addressing such matters as data protection and biologics. Much of the patent-related provisions of the TPP agreement are already consistent with Canadian law and/or proposed changes to Canadian law (based on, e.g., the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union).

The TPP agreement has not been signed nor ratified by Canada and will be the subject of consultation in Canada. If ratification occurs, it will not be for some time. An in-depth discussion regarding the TPP agreement as it relates to Canadian patent law is available here.

3. Law regarding patent validity

The Federal Court continued to see a significant number of cases with patent validity at issue. Rather than discuss every decision, the following briefly canvasses some of the interesting legal findings made, as well as the special case of Amgen.

The Courts continued to consider the tie between disclosure and utility. Justice Rennie’s 2014 Esomeprazole decision that there cannot be a disclosure requirement in cases of a sound prediction (except possibly for claims to a new use for an old compound) was cited with approval in Idenix v. Gilead2015 FC 1156. Further, on appeal, Justice Rennie’s decision was upheld; however, the FCA did not consider the disclosure requirement for sound prediction (2015 FCA 158, discussed here).

The interplay between disclosure and utility also arose in the context of demonstrated utility. Early in the year, an obiter statement in Laboratoires Servier v. Canada2015 FC 108, suggested that a patent must make reference to a study that demonstrates any promise made. Later in the year, Justice Gleason held in the Eli Lilly v. Apotex decision (2015 FC 1016) that there is no requirement to provide evidence of utility in a patent.

Regarding obviousness, the decision of Eli Lilly v. Mylan2015 FCA 286 (“Cialis FCA”), was released in December. In recent years, several decisions of the Federal Court considered whether something was obvious to try by asking whether the skilled person had good reason to pursue predictable solutions or solutions that provide a “fair expectation of success”. In Cialis FCA, Justice Dawson held that the “fair expectation of success” standard is inappropriate for determining whether an invention was obvious to try. Rather, Dawson JA framed the appropriate test as being whether the claimed invention was “more or less self-evident”.

The FCA called for clarification in two areas of the law in Cobalt v. Bayer (2015 FCA 116, discussed here). One issue was the standard of review for construction. In obiter, Stratas JA’s majority opinion questions whether a correctness standard is appropriate in considering construction in cases where the expert evidence played a significant role in informing the trial judge’s construction. In particular, Stratas JA discussed the artificiality required in “cleaving off” aspects of claim construction that flow from the trial judge’s appreciation of expert evidence from the words of the claim per se. Similar comments were made by Stratas JA in ABB Technology AG v. Hyundai Heavy Industries Co, Ltd (2015 FCA 181, discussed here).  Ultimately, the Court applied the correctness standard and left the question of the proper standard to be dealt with by the Supreme Court of Canada.

Cobalt v. Bayer also called for a thorough review of the method of medical treatment doctrine under Canadian law given that the statutory basis for the exception, the Patent Act’s old section 41(1), has been repealed.

Finally, the Amgen Canada v. Apotex2015 FC 1261 decision was the first Federal Court decision pertaining to a biologic under the PM(NOC) Regulationsas we discussed previously. The decision considered among other things the validity issues of anticipation and obviousness.

Apotex’s anticipation allegation was rejected because the prior art publication in question did not contain the same amino acid sequence as was claimed; in particular, the amino acid sequence in the prior art document did not begin with the amino acid “MET” as was required by the asserted claim.

However, the same prior art was relied on by Apotex in its successful obviousness allegation. In coming to this conclusion, Hughes J. noted that the work conducted by the inventors was “skilled work” as opposed to “creative work”, and that the prior art document provided a direct motivation to the skilled person to undertake the work that the Amgen inventors performed.

4. Pharmaceutical regulatory update

a. Data protection decisions

2015 was a relatively busy year in terms of data protection, with two decisions being issued by the Federal Court. In Photocure ASA v. Canada2015 FC 959, the Court upheld the Minister of Health’s denial of data protection to Cysview, an optical imaging agent designed to enhance detection of bladder cancer. In doing so, the Court found that the standard of review is reasonableness. This case is the first data protection judicial review to apply such a standard; all prior cases have applied the standard of correctness. The Court distinguished the established line of authority on the basis that questions of statutory interpretation were raised in those cases, while this case dealt merely with a question of fact. The state of data protection in Canada, and the Court’s application in Photocure, are discussed in detail here.

In the second data protection decision of 2015, Hospira Healthcare Corporation v. Canada (Health)2015 FC 1205, the Federal Court applied the established standard of correctness. ThePhotocure decision was confidential at the time Hospira was released, and therefore these two decisions stand in contrast to one another. Given the established line of authority in favour of a correctness standard, Photocure may simply be an outlier.

Notwithstanding the higher standard of correctness, the Court in Hospira upheld the Minister’s application of data protection to post-filing amendments to a drug submission. That is, the Court confirmed that if a post-filing amendment makes a direct or indirect reference to an innovative drug subject to data protection, then the data protection provisions apply and the drug under review cannot be approved until the data protection term expires. A thorough summary of this case can be found here.

b. Patent Register: rules on product specificity relaxed

Innovator pharmaceutical companies benefitted from a relaxing of the strict product specificity requirements for listing pharmaceutical patents on the Patent Register pursuant to thePM(NOC) Regulations. As a result of prior Federal Court decisions, a patent could only be listed on the Patent Register against a drug with multiple medicinal ingredients if the patent contained a claim specifying all of the medicinal ingredients. If one medicinal ingredient was missing, the patent was not listable. In 2015, the PM(NOC) Regulations were amended to specifically allow to be listed patents claiming only one out of multiple medicinal ingredients in the approved drug.3

The Federal Court of Appeal in Eli Lilly Canada Inc v. Canada (Minister of Health)2015 FCA 166 also relaxed the product specificity requirement. Prior to this decision, all medicinal ingredients in the approved drug had to be specifically named in the claim; it was not sufficient if the scope of the claim, as construed, included all medicinal ingredients. The Court of Appeal inEli Lilly changed this analysis, stating that the claims do not need to specifically name all medicinal ingredients; the claim, as construed, must simply match the medicinal ingredients in the approved product.

The drug at issue in this case was Trifexis (spinosad and milbemycin oxime). The claims at issue claimed oral formulations containing spinosad, where oral formulation was defined in the disclosure as potentially including many other known parasitic treatments such as “milbemycins”. The Court of Appeal found that the claims, as construed, claim an oral formulation of spinosad and milbemycin oxime, and therefore the patent was listable. The Court of Appeal’s reasons are discussed here.

c. Patented Medicines Prices Review Board has jurisdiction over generics

In Canada (Attorney General) v. Sandoz Canada Inc2015 FCA 249, the Federal Court of Appeal upheld the Board’s decision to retain jurisdiction over non-patent owners who sell patented medicines pursuant to a license or authorization from the patent owner (discussed here). Therefore, generic pharmaceutical companies Sandoz and ratiopharm were within the Board’s jurisdiction.

The Board also withstood a constitutional challenge to the extent that the Board retains jurisdiction over non-patent owners. The challenge from Sandoz and ratiopharm alleged that the Board’s current regime is one of pure price regulation and therefore intrudes into the Provinces’ constitutional jurisdiction over property and civil rights. The Court of Appeal dismissed the challenge, finding that there is an integral connection between the Board and patents. Specifically, the Board seeks to prevent the harm arising by reason of the existence of a patent pertaining to the medicine being sold. 

Leave to appeal to the Supreme Court of Canada has been sought by Sandoz and ratiopharm.

5. Competition Bureau setting its sights on patent matters

In recent years, the Competition Bureau has shown a greater interest in intellectual property matters.  Most recently, the Bureau released its Intellectual Property Enforcement Guidelines (IPEGs) in draft form for public consultation.  The draft IPEGs address, among other things, when and how the Bureau will investigate certain conduct involving intellectual property.  In this regard, the draft IPEGs provide guidance regarding:

  • Settlements under the PM(NOC) Regulations: where an innovator pharmaceutical company settles with a generic pharmaceutical company with respect to early (pre-patent expiry) market entry by the generic, the Bureau may investigate situations involving any payments for the purpose of delaying generic entry.  Factors such as the fair market value of the generic’s goods, the innovator’s potential section 8 damages exposure and the innovator’s litigation costs may be considered by the Bureau to determine the reasonableness of any payments.  In limited situations, the Bureau may investigate for criminal conspiracy violations, particularly where there is evidence that the intent of the payment was to fix prices, allocate markets or restrict output;
  • Conduct involving patent assertion entities (PAEs): PAEs that indiscriminately send cease and desist letters, or that are indifferent as to whether the allegations are misleading, may face liability for false or misleading representations, and/or deceptive marketing practices; and
  • Conduct involving standard essential patents (SEPs): where an entity fails to disclose patents that are essential during a standard-setting process (i.e., “patent ambush”), or where fair, reasonable and non-discriminatory licensing commitments are not respected, liability under the abuse of dominance provisions of the Competition Act may result.

At present, the IPEGs have not been finalized. The public consultation period ended on Aug. 10, 2015.